A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
Clinical trial NCT05885555 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05885555
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-16
- Primary completion
- 2025-02-05
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.